CUE Stock Summary and Trading Ideas (Cue Biopharma | NASDAQ:CUE)

Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.

Cue Biopharma trades on the NASDAQ stock market under the symbol CUE.

As of October 2, 2026, CUE stock price climbed to $25.57 with 155,963 million shares trading.

CUE has a beta of 3.80, meaning it tends to be more sensitive to market movements. CUE has a correlation of 0.07 to the broad based SPY ETF.

CUE has a market cap of $185.75 million. This is considered a Micro Cap stock.

Last quarter Cue Biopharma reported $8 million in Revenue and -$24.14 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$22.76.

In the last 3 years, CUE traded as high as $97.47 and as low as $4.97.

The top ETF exchange traded funds that CUE belongs to (by Net Assets): VTI, VXF, IWC, AVSC, AVTM.

CUE has outperformed the market in the last year with a return of +18.6%, while the SPY ETF gained +16.1%. However, in the most recent history, CUE shares have underperformed the stock market with its stock returning -9.5% in the last 3 month period and -31.0% for the last 2 week period, while SPY has returned +3.6% and +1.0%, respectively.

CUE support price is $22.81 and resistance is $27.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CUE shares will trade within this expected range on the day.